Message from the Director Dear Friends of UCI MIND, Please enjoy the latest issue of MIND Matters from UCI MIND. In this Spring issue, we highlight a number of exciting updates about the impact UCI MIND investigators are having in the field. On the cover, post-doctoral fellow Dr. Claire Butler highlights progress made by the collaborative MODEL-AD group, including a publication she led. Another post-doctoral fellow, Dr. Jessica Noche, highlights an exciting collaboration in which UCI MIND ...| UCI MIND
The FDA today announced that it will convene an advisory panel to review the data submitted to support potential approval of donanemab, a monoclonal antibody against the beta amyloid protein that demonstrated efficacy in early Alzheimer’s disease in a recent Phase 3 clinical trial. A positive decision to approve donanemab had been expected before the end of this month. Though data for donanemab’s ability to lower brain amyloid levels are convincing, the FDA had opted not to grant accelera...| UCI MIND